AUTHORS
Regis Peffault De Latour, MD, PhD, Jacques-Emmanuel Galimard2, Anna Grassi, MD3, Anna Maria Raiola, MD4, Alessandro Busca, MD5, Ibrahim Yakoub-Agha6, Francis Ayuk7, Pavel Zak, MD, PhD, PR8, Simona Sica, MD, PhD9, Alessandro Isidori10, Francesca Kinsella, PhD11, Jakob Passweg, MD, MS12, Etienne Daguindau13, Edouard Forcade, MD, PhD14, Peter Pal Remenyi, MD15, Simona Piemontese, MD16, Giorgia Battipaglia17, Jaime Sanz, MD, PhD18, Eolia Brissot, MD, PhD19
AFFILIATIONS
1 Saint-Louis Hospital, Paris, France
2 EBMT, Paris, France
3 ASST Papa Giovanni XXIII, Bergamo, Italy
4 IRCCS Ospedale Policlinico San Martino, Genova, Italy
5 S.S.C.V.D. Trapianto di Cellule Staminali, Città della Salute e della Scienza, Torino, Italy
6 CHU de Lille, Univ Lille, INSERM U1286, Infinite, Lille, France
7 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
8 Charles University Hospital, Hradec Králové, Czech Republic
9 Università Cattolica del Sacro Cuore, Rome, Italy
10 AORMN Hospital, Pesaro, Italy
11 Birmingham Centre for Cellular Therapy and Transplant, Birmingham, United Kingdom
12 University Hospital Basel, Basel, Switzerland
13 CHU Besancon Franche-Comte, Besancon, France
14 CHU Bordeaux, Hopital Haut-Leveque, Bordeaux, France
15 Del-pesti Centrumkorhaz, Budapest, Hungary
16 16Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
17 Department of Clinical Medicine and Surgery, Division of Hematology, Federico II University of Naples, Naples, Italy
18 Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia Departament de Medicina Universitat de Valencia, Valencia, Spain
19 Sorbonne University, service d'hématologie clinique et thérapie cellulaire Hôpital Saint-Antoine, APHP, Paris EBMT Study Unit, Paris, France
ABSTRACT
Introduction:
Myeloablative (MAC) fludarabine-busulfan (FB4) conditioning followed by 10/10 matched unrelated donor (MUD) peripheral blood stem cell (PBSC) transplantation (allo-HSCT) with antithymocyte globulin (ATG) represents a widely accepted standard platform for adults with acute myeloid leukemia (AML). Haploidentical transplantation with post-transplant cyclophosphamide (Haplo-PTCy) has emerged as an effective alternative donor strategy. However, several studies evaluating myeloablative conditioning (MAC) have reported increased acute and chronic graft-versus-host disease (GVHD) with PBSC grafts in the haploidentical setting, leading many centers to preferentially use bone marrow (BM) for MAC Haplo-PTCy allo-HSCT. Whether myeloablative haploidentical BM (instead of PBSC) transplantation with PTCy provides outcomes comparable to the current standard FB4 MUD PBSC platform remains unknown. We therefore compared these two contemporary transplant strategies using EBMT registry data.
Methods:
Adult patients undergoing a first MAC allo-HCT for AML in first complete remission between 2011 and 2023 were identified in the EBMT registry. Included patients received MAC Haplo-PTCy BM after Fludarabine, Busulfan (9.6 mg/kg total dose) and Thiothepa (10 mg/kg total dose) (the MAC-Haplo-BM-PTCy group) or standard MAC MUD PBSC ATG after Fludarabine and Busulfan (12.8 mg/kg total dose, FB4) (the MAC-MUD-PBSC group). The initial cohort comprised 963 patients, including 278 patients who received Haplo-BM-PTCy and 685 who received MUD-PBSC. A matched-pair analysis based on recipient age, transplant year, Karnofsky Performance Status, HCT-CI, ELN2022 AML cytogenetic risk, secondary AML, and sex resulted in 701 well-balanced patients (262 Haplo-BM-PTCy and 439 MUD-PBSC). The primary endpoint was overall survival (OS). Secondary endpoints included hematopoietic recovery, leukemia-free survival (LFS), relapse incidence (RI), non-relapse mortality (NRM), acute and chronic GVHD, GVHD-free relapse-free survival (GRFS).
Results:
Among the 701 patients (262 Haplo-PTCy and 439 MUD) identified for the matched-pair analysis, the median age was 46.1 years (Q1:34.7 - Q3:54.4) and there were 322 females (45.9%). Median time between AML diagnosis and allo-HSCT was 5.2 months (Q1:4.2 – Q3:6.5). AML risks were intermediate for 374 patients (67.8%) and adverse for 130 patients (23.6%). As expected with BM grafts, neutrophil and platelet engraftment occurred later in the MAC-Haplo-BM-PTCy group. With a median follow-up of 4.7 years, the 2-year OS was not different between the MAC-Haplo-BM-PTCy and the MAC-MUD-PBSC groups (76.4% vs 76.9%; HR 0.96, 95% CI 0.72–1.28; p=0.78). First cause of death was relapse for both groups (n=34, 47.9% for the MAC-Haplo-BM-PTCy group and n=80, 67.2% for the MAC-MUD-PBSC group) followed by infections (n=17, 23.9% and n=20, 16.8%, respectively). No significant differences were observed for LFS (71.1% vs 68.1%; HR 0.84, 95% CI 0.65–1.08; p=0.18) or GRFS (56.7% vs 53.3%; HR 0.82, 95% CI 0.65–1.05; p=0.11) between the MAC-Haplo-BM-PTCy and the MAC-MUD-PBSC groups, respectively. MAC-Haplo-BM-PTCy transplantation was associated with a significantly lower 2-year relapse incidence (14.9% vs 24.1%; HR 0.60, 95% CI 0.43–0.84; p=0.003). This advantage was offset by a non-significant increase in NRM (13.9% vs 7.8%; HR 1.53, 95% CI 0.97–2.42; P=0.07) in the MAC-Haplo-BM-PTCy group vs MAC-MUD-PBSC group, respectively. Cumulative incidence of grade II-IV acute GVHD (100 days: 22.0% vs 24.7%; P=0.58), grade III-IV acute GVHD (100 days: 6.3% vs 6.3%; P=0.95), chronic GVHD (2 years: 28.7% vs 34.6%; P=0.21), and moderate/severe/extensive chronic GVHD (2 years: 12.8% vs 18.4%; P=0.20) were not different between the MAC-Haplo-BM-PTCy group and the MAC-MUD-PBSC groups, respectively.
Conclusions:
Among adults with AML undergoing myeloablative allo-HSCT, Haplo-BM-PTCy achieved overall survival comparable to the current standard FB4-ATG MUD-PBSC platform, while providing superior relapse control without excess GVHD. These findings support bone marrow-based haploidentical transplantation with PTCy as a valid alternative donor strategy in the MAC setting.
DISCLOSURES
Regis Peffault De Latour, MD, PhD: MSD - Honoraria; Amgen - Honoraria; Pfizer - Honoraria; Roche - Honoraria; Jazz - Honoraria; Sanofi - Honoraria; Alexion - Honoraria; Novartis - Honoraria; Sobi - Honoraria; Pfizer - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)